Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
The original release is unavailable here.
Pasithea Therapeutics Corp. on 6ix
Story so far
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
- Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
Earlier from Pasithea Therapeutics
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
- Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
- Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
- Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
Later from Pasithea Therapeutics
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
- Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Follow Pasithea Therapeutics into a list and get an email when it puts out news.
Follow Pasithea Therapeutics